Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme

Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities

(2018) Jae Eun Cheong et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells

(2017) Giada Mondanelli et al.   IMMUNITY

Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR)

(2017) Seung-Hyeon Seok et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health

(2017) Igor Cervenka et al.   SCIENCE

Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor

(2017) Benjamin J. Moyer et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

The end of the road for the tryptophan depletion concept in pregnancy and infection

(2016) A. A.- B. Badawy et al.   CLINICAL SCIENCE

Stress Kinase GCN2 Controls the Proliferative Fitness and Trafficking of Cytotoxic T Cells Independent of Environmental Amino Acid Sensing

(2016) Lee-Ann Van de Velde et al.   Cell Reports

The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas

(2016) Jana K. Sonner et al.   OncoImmunology

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors

(2016) Rikke B. Holmgaard et al.   EBioMedicine

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

(2015) Soranobu Ninomiya et al.   BLOOD

IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII

(2015) Davide Matino et al.   JOURNAL OF CLINICAL INVESTIGATION

Accumulation of an Endogenous Tryptophan-Derived Metabolite in Colorectal and Breast Cancers

(2015) Paolo Puccetti et al.   PLoS One

Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

(2014) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease

(2013) Amos A. Fatokun et al.   AMINO ACIDS

Structure and mechanism of kynureninase

(2013) Robert S. Phillips   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study

(2013) D. Theofylaktopoulou et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

IDO1 Metabolites Activate β-catenin Signaling to Promote Cancer Cell Proliferation and Colon Tumorigenesis in Mice

(2013) Ameet I. Thaker et al.   GASTROENTEROLOGY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion

(2012) M. Platten et al.   CANCER RESEARCH

Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation

(2012) Vera Levina et al.   Clinical & Developmental Immunology

Kynurenines in the CNS: recent advances and new questions

(2012) László Vécsei et al.   NATURE REVIEWS DRUG DISCOVERY

Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy

(2011) Everett Stone et al.   JOURNAL OF CONTROLLED RELEASE

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

(2011) Christiane A. Opitz et al.   NATURE

Possible roles of excess tryptophan metabolites in cancer

(2010) King-Thom Chung et al.   ENVIRONMENTAL AND MOLECULAR MUTAGENESIS

An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells

(2010) J. D. Mezrich et al.   JOURNAL OF IMMUNOLOGY

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

(2010) J Rafael Sierra et al.   Molecular Cancer

Tumor immunogenicity and responsiveness to cancer vaccine therapy: The state of the art

(2010) Taylor H. Schreiber et al.   SEMINARS IN IMMUNOLOGY

In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer

(2009) Franck Pagès et al.   JOURNAL OF CLINICAL ONCOLOGY

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

(2008) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA